Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇳🇿NZ · Medicine#188500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
150 to 900🎙 Daily cadence·377 episodes·Last published today - Monthly Reach
Unique listeners across all episodes (30 days)
500 to 3K🇳🇿100% - Active Followers
Loyal subscribers who consistently listen
275 to 1.6K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Smartphone Assessment of Daytime Insomnia Symptoms With Suvorexant
May 12, 2026
Unknown duration
3D-Printed Tympanostomy Tube Design Optimized With Neural Networks
May 11, 2026
Unknown duration
Adagio Ventricular Ablation Tech Performs Well In Clinical Trial
May 11, 2026
Unknown duration
Motif Neurotech Gets FDA IDE To Study Brain Implant In Depression
May 11, 2026
Unknown duration
Chronic Kidney Disease Screening Via Mobile Health Units
May 11, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5/12/26 | Smartphone Assessment of Daytime Insomnia Symptoms With Suvorexant | Smartphone-based ecological momentary assessment captured real-time insomnia symptoms and daytime functioning, offering clinicians a sensitive tool to personalize treatment, monitor safety, and improve outcomes. | — | ||||||
| 5/11/26 | 3D-Printed Tympanostomy Tube Design Optimized With Neural Networks | A data-driven framework using neural networks and 3D validation optimized tympanostomy tube design, improving drainage efficiency and advancing machine learning applications in medical device engineering | — | ||||||
| 5/11/26 | Adagio Ventricular Ablation Tech Performs Well In Clinical Trial | New cryoablation technology for ventricular tachycardia may simplify treatment, reduce ICD shocks and medication dependence, and improve long term patient quality of life over time | — | ||||||
| 5/11/26 | Motif Neurotech Gets FDA IDE To Study Brain Implant In Depression | Motif Neurotech’s implantable depression device may expand treatment options through minimally invasive brain stimulation, offering personalized at-home therapy for patients with treatment-resistant depression. | — | ||||||
| 5/11/26 | Chronic Kidney Disease Screening Via Mobile Health Units | Mobile chronic kidney disease screening may improve early detection, expand access for underserved populations, and support prevention-focused care through timely follow-up, treatment, and community outreach. | — | ||||||
| 5/7/26 | Exploring Sexual Dysfunction in Women with Parkinson’s Disease | Addressing sexual dysfunction in women with Parkinson’s disease may improve quality of life through better communication, tailored treatments, routine assessments, and more holistic multidisciplinary care. | — | ||||||
| 5/7/26 | New Strategies Against Brain Tumors | Emerging glioblastoma research is advancing immune-targeted therapies and innovative treatment strategies, offering hope for improved survival, stronger treatment responses, and better quality of life outcomes. | — | ||||||
| 5/7/26 | Post-Meal Blood Sugar Spikes May Raise Alzheimer’s Risk | Emerging research links post-meal blood sugar spikes with higher Alzheimer’s risk, highlighting glucose control, insulin resistance management, and lifestyle interventions as important strategies for brain health. | — | ||||||
| 5/7/26 | The End of the “Wait and See” Era: How Blood Tests Are Revolutionizing Neurology | High-accuracy Alzheimer’s blood tests using biomarkers like p-tau217 may enable earlier, more accessible diagnosis, improving treatment access, precision staging, and personalized neurodegenerative care worldwide. | — | ||||||
| 5/6/26 | Estradiol Patch Matches Standard Hormone Therapy in Phase 3 Trial: A New First-Line Option for Menopause | Estradiol patch shows comparable efficacy to oral hormone therapy for menopause symptoms, offering a convenient transdermal option that may improve safety, adherence, and personalized treatment choices. | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 5/6/26 | ctDNA in Early Breast Cancer: Prognostic Power vs Clinical Actionability | Circulating tumor DNA helps detect minimal residual disease and predict recurrence risk in early breast cancer, but its role in guiding treatment decisions remains promising yet unproven. | — | ||||||
| 5/6/26 | Cost-Effectiveness of Point-of-Care HCV RNA Testing in US | Point-of-care HCV RNA testing enables same-visit diagnosis and treatment, improving cure rates, reducing transmission, and proving cost-effective by minimizing follow-up loss and long-term complications. | — | ||||||
| 5/5/26 | CYP2C19 Genetic Testing Guides Personalized Blood Thinner Therapy | CYP2C19 genetic testing is emerging as a practical tool to tailor antiplatelet therapy for people who need blood thinners after a heart attack, stent placement, or other vascular events. Clinicians are starting to use simple genetic results to decide whether the standard drug will work or whether a different medicine is safer and more effective for an individual patient. | — | ||||||
| 5/5/26 | Warfarin Self-Management in U.S. Health Care: Nonrandomized Trial | Warfarin self-management empowers patients to monitor INR and adjust dosing, improving control and outcomes while reducing clinic burden, though requiring careful training, oversight, and equitable access. | — | ||||||
| 5/4/26 | Why Some Men May Struggle to Open Up Emotionally | Men’s mental health is often overlooked due to stigma around emotional expression, delaying support and increasing risk of crisis, highlighting need for proactive, normalized, and accessible care strategies. | — | ||||||
| 5/4/26 | FDA recommends guidance Revision Over Dialysis System Tubing Concern | The Food and Drug Administration updated Prismaflex guidance highlights tubing-related risks, urging vigilance to prevent air-in-blood events and ensure safe, uninterrupted renal replacement therapy in critical care settings. | — | ||||||
| 5/4/26 | Surgeons Drive Momentum for Robotics in Acute Care Settings | Robotic-assisted surgeries, led by da Vinci Surgical System, are expanding rapidly, improving efficiency, outcomes, and competition while driving adoption, innovation, and investment across modern healthcare systems. | — | ||||||
| 5/4/26 | Cerebral Oximetry’s Impact on Oxygenation in Preterm Infants | Monitoring cerebral oxygenation in extremely preterm infants enables early intervention to prevent brain injury, improve survival, guide NICU care, and support better long-term neurodevelopmental outcomes. | — | ||||||
| 5/4/26 | Extending Mental Health Interventions Beyond Therapy Settings | Digital tools, wearables, and AI extend therapy beyond sessions, enabling real-time support, earlier intervention, and personalized care, while requiring updated reimbursement models, privacy safeguards, and clinician workflows. | — | ||||||
| 5/1/26 | Fetal Alcohol Spectrum Disorder (FASD): Understanding Its Lifelong Mental Health Impact | Fetal Alcohol Spectrum Disorder is a lifelong neurodevelopmental condition caused by prenatal alcohol exposure, leading to cognitive, behavioral, and mental health challenges requiring early diagnosis, coordinated care, and support. | — | ||||||
| 5/1/26 | Narcolepsy Comorbidities and Their Symptom Profiles: What Clinicians and Patients Should Know | Narcolepsy often coexists with psychiatric, respiratory, and metabolic conditions, complicating diagnosis and treatment, requiring comprehensive, multidisciplinary care to improve safety, functioning, and long-term patient outcomes. | — | ||||||
| 5/1/26 | Big Ideas from the 2026 American Academy of Neurology Annual Meeting (AAN): What’s Changing in Brain Health and Why It Matters | The 2026 American Academy of Neurology Annual Meeting 2026 highlights neurology’s shift toward biomarker-driven diagnosis, personalized care, emerging therapies, and ongoing challenges in access, cost, and real-world implementation. | — | ||||||
| 5/1/26 | Wrap-Up: Vyvgart Targets Four Populations at AAN 2026 | AAN 2026 highlights transformative ADAPT data, expanding Vyvgart across MG subtypes and CIDP, signaling targeted biologics, pediatric advances, and urgent updates to managed care coverage frameworks. | — | ||||||
| 4/30/26 | Vyvgart Hytrulo Challenges the Step Therapy Model in Treatment-Naive CIDP | Post hoc ADHERE analysis shows Vyvgart Hytrulo delivers early responses in 87.5% of treatment-naive CIDP patients, challenging step-therapy policies and prompting reconsideration of first-line treatment strategies. | — | ||||||
Showing 24 of 437
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.